Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy

Journal of Viral Hepatitis

Volumn 17, Issue 3, 2010, Pages 178-184

  Wang, L C ^a   Chen, E Q ^a   Cao, J ^b   Liu, L ^a   Wang, J R ^a   Lei, B J ^a   Tang, H ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Adefovir dipivoxil; Combination therapy; Hepatitis B; Lamivudine

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MONOTHERAPY; MUTATION; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL;

ADENINE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; DRUG TOXICITY; ENZYMES; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER FUNCTION TESTS; MALE; PHOSPHONIC ACIDS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 75149180038     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01164.x     Document Type: Article

References (28)

1. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEAL-HBV study. Clin Liver Dis 2007 11 (4 797 816. viii.
2. Delaney WEt. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. J Antimicrob Chemother 2007 59 (5 827 832.
3. Sokal EM, Kelly D, Wirth S, Mizerski J, Dhawan A, Frederick D. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. J Clin Pharmacol 2008 48 (4 512 517.
4. Akyildiz M, Karasu Z, Zeytunlu M, Aydin U, Ozacar T, Kilic M. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 2007 22 (12 2130 2134.
5. Lim SG, Marcellin P, Tassopoulos N et al. Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther 2007 26 (10 1419 1428.
6. Pallier C, Rodriguez C, Brillet R, Nordmann P, Hezode C, Pawlotsky JM. Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology 2009 49 (1 50 59.
7. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004 351 (15 1521 1531.
8. Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol 2008 23 (8 Pt 1 1182 1192.
9. Veenstra DL, Spackman DE, Di Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther 2008 27 (12 1240 1252.
10. Buti M, Elefsiniotis I, Jardi R et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol 2007 47 (3 366 372.
11. Bottecchia M, Madejon A, Sheldon J, Garcia-Samaniego J, Barreiro P, Soriano V. Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. J Antimicrob Chemother 2008 62 (3 626 627.
12. Papatheodoridis GV, Deutsch M. Resistance issues in treating chronic hepatitis B. Future Microbiol 2008 3: 525 538.
13. Marcellin P, Asselah T, Boyer N. Treatment of chronic hepatitis B. J Viral Hepat 2005 12 (4 333 345. (Pubitemid 40961472)
14. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2008 28 (2 167 177.
15. Keeffe EB, Zeuzem S, Koff RS et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007 5 (8 890 897.
16. Yim HJ. Management of antiviral-resistant chronic hepatitis B virus infection. Korean J Gastroenterol 2008 51 (6 346 359.
17. Balsano C, Alisi A. Viral hepatitis B: established and emerging therapies. Curr Med Chem 2008 15 (9 930 939.
18. Ijaz S, Arnold C, Dervisevic S et al. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J Med Virol 2008 80 (7 1160 1170.
19. Yatsuji H, Suzuki F, Sezaki H et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008 48 (6 923 931.
20. Hui CK, Zhang HY, Bowden S et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008 48 (5 714 720.
21. Zoulim F, Parvaz P, Marcellin P et al. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver Int 2009 29 (3 420 426.
22. Lacey L, Chien RN, Chuang WL, Pwu RF. Economic evaluation of chronic hepatitis B treatments in Taiwan. J Gastroenterol Hepatol 2008 23 (4 571 579.
23. Sun X, Qin WX, Li YP, Jiang XH. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence. J Gastroenterol Hepatol 2007 22 (9 1369 1377.
24. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007 133 (5 1445 1451.
25. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006 131 (6 1743 1751.
26. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008 359 (23 2442 2455.
27. Asselah T, Lada O, Moucari R, Marcellin P. Clevudine: a promising therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2008 17 (12 1963 1974.
28. European Association For The Study Of The L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009 50 (2 227 242.